



PALLA PHARMA

ASX ANNOUNCEMENT

Wednesday 1 September 2021

Extension of Reporting Deadline for Interim Financial Report

Further to the announcement of 30 August 2021, Palla Pharma Limited (ASX: PAL) (the Company) advises that the Company is relying on the Amended ASIC Relief (Extended Reporting and Lodgement Deadlines – Listed Entities) instrument 2020/451 and the ASX Class Waiver to extend the lodgement date for its audited half-year accounts required to be lodged with ASIC and ASX under section 320 of the Corporations Act 2001 (Cth) and Listing Rule 4.2B respectively.

Under the relief, the deadline for lodgement of half-year year financial reports, including the directors' reports and auditor's reports, for entities with balance dates up to and including 7 July 2021 is extended by one month after half-year end. Accordingly, the Company will have an additional month to lodge its audited half-year financial statements for the half-year ended 30 June 2021.

The Company will provide a further update ahead of the extended deadline if there is a material difference between its Appendix 4D (released on 31 August 2021) and its audited half-year financial statements by way of an ASX announcement on the ASX Market Announcements Platform.

This announcement has been authorised for release by the Chairman.

For more information please contact:

Simon Moore

Chairman
Palla Pharma Limited
+61 3 9301 0800

Brendan Middleton

Interim CEO
Palla Pharma Limited
+61 3 9301 0800

About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.

Palla Pharma Limited

PO Box 2139 Melbourne, VIC 3001, Australia

T +61 3 9301 0800 / F +61 3 9301 0899 / W pallapharma.com / E info@pallapharma.com